Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) Market Outlook
Thelansis’s “Relapsed or Refractory
Peripheral T-Cell Lymphoma (r/r PTCL) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2024 To 2034" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Relapsed
or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Relapsed
or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) Overview
Peripheral
T-cell lymphoma (PTCL) is a rare group of typically fast-growing Non-Hodgkin’s
Lymphomas (NHL) that originates from mature T-cells and natural killer (NK)
cells, which are mature-stage white blood cells. This subtype of NHL
specifically affects T-cells and occurs when these cells develop and
proliferate abnormally. Patients diagnosed with PTCL often face a grim
prognosis characterized by multiple relapses and resistance to initial
treatment. Relapsed or Refractory Peripheral T-cell lymphoma refers to a
condition where the disease reappears or grows again after a period of
remission (relapsed) or when the lymphoma does not respond to treatment
(refractory), meaning that the cancer cells continue to grow, or when the
response to treatment does not last very long. Median overall survival for
relapsed patients had a longer survival period at 29.1 months compared to
refractory patients with only 12.3 months. One-year survival rates are
influenced by the response to the initial therapy, with 84% survival among
relapsed patients and 52% among refractory patients. Among all relapsed and
refractory patients, those achieving a complete response to second-line therapy
had a notably extended survival compared to those with a partial response or
worse. Recently, the FDA approved four next-generation drugs (pralatrexate,
romidepsin, brentuximab vedotin, and belinostat) for treating relapsed and
refractory PTCL based on their response rates. However, none of these agents
led to improvements in overall survival. The European Medicines Agency (EMA)
declined to approve both pralatrexate and romidepsin due to a lack of clear
clinical benefits, and belinostat is not licensed in Europe despite being
granted orphan designation status by the EMA. Brentuximab vedotin is the only
drug approved by the EMA to treat relapsed or refractory systemic ALCL,
primarily due to a more favorable benefits-to-risks ratio.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment